Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00504309 · ClinicalTrials.gov registry record · NA

Vascular and Lipid Effects of Omega-3 Fatty Acids in People With Moderately Elevated Triglycerides

A NA study of Hypertriglyceridemia, sponsored by Penn State University.

Completed
Registry status
NA
Development phase
28
Enrollment target
1
Study location

NCT00504309: Completed NA study of Hypertriglyceridemia, sponsored by Penn State University.

NCT00504309 is a NA study of Hypertriglyceridemia that has completed, run by Penn State University. The registered enrollment target is 28 participants, below the 175-participant average among 25 other Hypertriglyceridemia trials with a reported enrollment target (84% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00504309, a NA study of Hypertriglyceridemia, has completed, sponsored by Penn State University.

COMPLETED
Registry status
NA
Development phase
28 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to evaluate the cardiovascular and lipid effects of two doses of an omega-3 fatty acid concentrate in a group of people who normally are not treated for high lipids.

Primary Outcome

Plasma/serum samples were analyzed at baseline and at the end of each 8-week treatment period to evaluate the effect of P-OM3 dose on triglycerides, HDL-C, LDL-C, and total cholesterol.

Conditions Studied

Interventions

  • DRUG 4/day of 4g P-OM3 capsules
  • DRUG 4/day of 1g P-OM3 capsules
  • DRUG Corn Oil Placebo, 4 capsules/day for 8 weeks

Study Locations (1)

Pennsylvania

  • Penn State University General Clinical Research Center - University Park

Trial Details

FieldValue
Enrollment Target 28 participants
Start Date 2007-07
Est. Completion 2009-01
Phase NA
Penn State University

219 total trials

What the finished NCT00504309 record still lists

NCT00504309 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 28 participants, a relatively small participant target, below the 175-participant average among 25 other Hypertriglyceridemia trials with a reported enrollment target (84% lower).

The record links to 1 condition, with Hypertriglyceridemia appearing as the primary indexed condition, and to 3 interventions - of which 4/day of 4g P-OM3 capsules is the first listed.

NCT00504309 reports a single indexed study location in Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT00504309 about?

NCT00504309 is a clinical study titled "Vascular and Lipid Effects of Omega-3 Fatty Acids in People With Moderately Elevated Triglycerides". The purpose of this study is to evaluate the cardiovascular and lipid effects of two doses of an omega-3 fatty acid concentrate in a group of people who normally are not treated for high lipids.

What is the current status of trial NCT00504309?

This trial is currently completed. It is a NA study. The enrollment target is 28 participants. The study started on 2007-07. Estimated completion is 2009-01.

What conditions does trial NCT00504309 study?

This clinical trial studies the following conditions: Hypertriglyceridemia.

What interventions are being tested in trial NCT00504309?

The interventions under investigation include: 4/day of 4g P-OM3 capsules (DRUG), 4/day of 1g P-OM3 capsules (DRUG), Corn Oil Placebo, 4 capsules/day for 8 weeks (DRUG).

Who is sponsoring clinical trial NCT00504309?

This trial is sponsored by Penn State University, which has 219 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00504309 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Hypertriglyceridemia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00504309's enrollment target sits among peer trials

28 20th of 25 higher than 6 of 25 other Hypertriglyceridemia trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Hypertriglyceridemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03471117 · 28 participants · Phase 4

    Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients

  • NCT03523975 · 28 participants · Phase 1

    Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma

  • NCT03608631 · 28 participants · Phase 1

    iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation

  • NCT03810651 · 28 participants · Early Phase 1

    Pencil Beam Scanning in Patients With Renal Tumors

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00504309, the US trial registry maintained by the National Library of Medicine. NCT00504309 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.